ATE385798T1 - Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen - Google Patents

Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen

Info

Publication number: ATE385798T1
Authority: AT; Austria
Prior art keywords: azd2171; human; azd; pharmaceutical preparations; preparations containing
Prior art date: 2003-07-10

Application number

AT04743280T

Other languages

English (en)

Inventor

Stephen Robert Wedge

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-10

Filing date

2004-07-07

Publication date

2008-03-15

2004-07-07 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2008-03-15 Application granted granted Critical

2008-03-15 Publication of ATE385798T1 publication Critical patent/ATE385798T1/de

Links

XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 title abstract 6
229960002412 cediranib Drugs 0.000 title abstract 6
239000000825 pharmaceutical preparation Substances 0.000 title 1
241001465754 Metazoa Species 0.000 abstract 3
206010028980 Neoplasm Diseases 0.000 abstract 3
238000004519 manufacturing process Methods 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
230000001772 anti-angiogenic effect Effects 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
230000005855 radiation Effects 0.000 abstract 2
230000001603 reducing effect Effects 0.000 abstract 2
230000008728 vascular permeability Effects 0.000 abstract 2
239000013066 combination product Substances 0.000 abstract 1
229940127555 combination product Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Iron Core Of Rotating Electric Machines (AREA)

AT04743280T 2003-07-10 2004-07-07 Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen ATE385798T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0316123.9A GB0316123D0 (en)	2003-07-10	2003-07-10	Combination therapy

Publications (1)

Publication Number	Publication Date
ATE385798T1 true ATE385798T1 (de)	2008-03-15

Family

ID=27741905

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04743280T ATE385798T1 (de)	2003-07-10	2004-07-07	Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen

Country Status (17)

Country	Link
US (1)	US20060160775A1 (de)
EP (1)	EP1651227B1 (de)
JP (1)	JP2007526887A (de)
KR (1)	KR20060034287A (de)
CN (1)	CN100435799C (de)
AT (1)	ATE385798T1 (de)
AU (1)	AU2004255023B2 (de)
BR (1)	BRPI0412450A (de)
CA (1)	CA2531643A1 (de)
DE (1)	DE602004011781T2 (de)
ES (1)	ES2299841T3 (de)
GB (1)	GB0316123D0 (de)
IL (1)	IL172682A0 (de)
MX (1)	MXPA06000413A (de)
NO (1)	NO20056171L (de)
WO (1)	WO2005004871A1 (de)
ZA (1)	ZA200600188B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0008269D0 (en)	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent
US20080113039A1 (en) *	2004-03-23	2008-05-15	Stephen Robert Wedge	Combination Therapy
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
WO2007003933A2 (en) *	2005-07-06	2007-01-11	Astrazeneca Ab	Combination therapy of cancer with azd2171 and gemcitabine
CA2631676A1 (en) *	2005-12-22	2007-06-28	Astrazeneca Ab	Combination of azd2171 and pemetrexed
TW200922590A (en) *	2007-09-10	2009-06-01	Curis Inc	VEGFR inhibitors containing a zinc binding moiety

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9714249D0 (en) *	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
JP2002518341A (ja) *	1998-06-15	2002-06-25	アーチ・デヴェロップメント・コーポレイション	放射線療法と抗血管形成因子の組み合わせ
BRPI0017548B8 (pt) *	1999-02-10	2023-05-02	Astrazeneca Ab	Composto
DE60111622T2 (de) *	2000-03-31	2006-05-18	Angiogene Pharmaceuticals Ltd.	Getrennte dosis therapien mit gefässschädigender aktivität
EE200200565A (et) *	2000-03-31	2004-06-15	Angiogene Pharmaceuticals Ltd.	Vaskulaarse kahjustava toimega kombinatsioonravi
GB0008269D0 (en) *	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy

2003
- 2003-07-10 GB GBGB0316123.9A patent/GB0316123D0/en not_active Ceased
2004
- 2004-07-07 CA CA002531643A patent/CA2531643A1/en not_active Abandoned
- 2004-07-07 AU AU2004255023A patent/AU2004255023B2/en not_active Ceased
- 2004-07-07 JP JP2006518354A patent/JP2007526887A/ja active Pending
- 2004-07-07 KR KR1020067000639A patent/KR20060034287A/ko not_active Ceased
- 2004-07-07 DE DE602004011781T patent/DE602004011781T2/de not_active Expired - Fee Related
- 2004-07-07 CN CNB2004800194887A patent/CN100435799C/zh not_active Expired - Fee Related
- 2004-07-07 ES ES04743280T patent/ES2299841T3/es not_active Expired - Lifetime
- 2004-07-07 AT AT04743280T patent/ATE385798T1/de not_active IP Right Cessation
- 2004-07-07 BR BRPI0412450-2A patent/BRPI0412450A/pt not_active IP Right Cessation
- 2004-07-07 EP EP04743280A patent/EP1651227B1/de not_active Expired - Lifetime
- 2004-07-07 MX MXPA06000413A patent/MXPA06000413A/es active IP Right Grant
- 2004-07-07 WO PCT/GB2004/002937 patent/WO2005004871A1/en not_active Ceased
- 2004-07-07 US US10/563,440 patent/US20060160775A1/en not_active Abandoned
2005
- 2005-12-19 IL IL172682A patent/IL172682A0/en unknown
- 2005-12-23 NO NO20056171A patent/NO20056171L/no not_active Application Discontinuation
2006
- 2006-01-09 ZA ZA200600188A patent/ZA200600188B/xx unknown

Also Published As

Publication number	Publication date
EP1651227A1 (de)	2006-05-03
NO20056171L (no)	2006-02-07
AU2004255023A1 (en)	2005-01-20
CA2531643A1 (en)	2005-01-20
ZA200600188B (en)	2007-04-25
US20060160775A1 (en)	2006-07-20
DE602004011781T2 (de)	2009-02-19
AU2004255023B2 (en)	2007-09-27
CN1819830A (zh)	2006-08-16
BRPI0412450A (pt)	2006-09-19
CN100435799C (zh)	2008-11-26
GB0316123D0 (en)	2003-08-13
WO2005004871A1 (en)	2005-01-20
IL172682A0 (en)	2006-04-10
MXPA06000413A (es)	2006-03-17
KR20060034287A (ko)	2006-04-21
DE602004011781D1 (de)	2008-03-27
ES2299841T3 (es)	2008-06-01
JP2007526887A (ja)	2007-09-20
EP1651227B1 (de)	2008-02-13
HK1089384A1 (en)	2006-12-01

Legal Events

Date	Code	Title	Description
2008-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
GB0223380D0 (en)	2002-11-13	Combination therapy
MXPA04004355A (es)	2004-08-11	Tratamiento de combinacion que comprende zd6474 y un taxano.
CY1111547T1 (el)	2015-08-05	Συνδυασμος zd6474 και πεμετρεξεδης
CY1111482T1 (el)	2015-08-05	Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003506A (es)	2007-05-10	Terapia de combinacion de cancer que comprende azd2171 e imatinib.
MX2007003505A (es)	2007-05-10	Combinacion que comprende zd6474 e imatinib.
MXPA05008583A (es)	2005-11-04	Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
PL1653964T3 (pl)	2009-01-30	Skojarzone leczenie raka obejmujące AZD2171 i ZD1839
DE602004011781D1 (de)	2008-03-27	Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen
NO20064755L (no)	2006-10-20	Kombinasjonsterapi
ATE447973T1 (de)	2009-11-15	Kombinationstherapie mit azd-2171
WO2005092384A3 (en)	2006-11-02	Combination therapy with azd2171 and a platinum anti-tumour agent
DE60308403D1 (de)	2006-10-26	Kombinationstherapie mit gemzitabin und zd6126